Please assess the completion status of the following clinical trial:

Trial Title: Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~Inclusion criteria:~* Histologically confirmed non-small cell lung cancer~  * Stage I-IIIA disease~* Must have undergone a complete resection~* Must begin adjuvant chemotherapy within 8 weeks of surgical resection~PATIENT CHARACTERISTICS:~* Eastern Cooperative Oncology Group (ECOG) performance status 0-1~* Absolute neutrophil count ≥ 1,500/mm\^3~* Hemoglobin ≥ 8.0 g/dL~* Platelet count ≥ 100,000/mm\^3~* Serum creatinine normal OR creatinine clearance ≥ 40 mL/min~* Bilirubin normal~* Alkaline phosphatase (AP), Aspartate aminotransferase (AST), and Alanine transaminase (ALT) must meet 1 of the following criteria:~  * AP normal AND AST and ALT ≤ 5 times upper limit of normal (ULN)~ * AP ≤ 2.5 times ULN AND AST and ALT ≤ 1.5 times ULN~ * AP ≤ 5 times ULN AND AST and ALT normal~* Negative pregnancy test~* Fertile patients must use effective contraception during and for at least 3 months after study therapy~Exclusion criteria:~* Patients with a history of severe hypersensitivity to docetaxel or polysorbate 80 are excluded.~* Women who are currently or planning to breast feed.~* Those with peripheral neuropathy ≥ grade 2~PRIOR CONCURRENT THERAPY:~* 2-8 weeks since prior surgery and recovered

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Single Arm Trial (Type: OTHER): adjuvant carboplatin plus docetaxel carboplatin area under curve (AUC) = 6 IV on day 1 every 3 weeks for 4 cycles docetaxel 75 mg/m² IV on day 1 every 3 weeks for 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).